Adults with COPD who used inhaled corticosteroids for more than 24 months faced higher risks for diabetes, osteoporosis, ...

Dupilumab improved exacerbations and lung function in patients with COPD and T2 inflammation, regardless of baseline BODE index score.

Inhaled corticosteroids (ICS), short- and long-acting β 2-agonists (SABA and LABA), long-acting muscarinic antagonists (LAMA) and fixed-dose combinations of LABA and ICS are the cornerstones of ...

The FDA has requested five large clinical trials to evaluate fixed-dose ICS–LABA products with the primary outcome of life-threatening asthma exacerbation or death. The results will not be ...

Current maintenance or controller treatments for COPD include tiotropoium, LAMA, LABA, LABA + ICS, LAMA + LABA, roflumilast, theophylline, and 'triple therapy' combining LAMA + LABA + ICS.

which was reported at last year's ERS and showed that withdrawing the steroid component from triple therapy with LAMA/LABA/ICS had no impact on exacerbation rates in COPD. That trial was not ...